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Abstract Metastasis in lung cancer is a multifaceted process.
In this review, we will dissect the process in several isolated
steps such as angiogenesis, hypoxia, circulation, and establish-
ment of a metastatic focus. In reality, several of these processes
overlap and occur even simultaneously, but such a presenta-
tion would be unreadable. Metastasis requires cell migration
toward higher oxygen tension, which is based on changing the
structure of the cell (epithelial-mesenchymal transition), orien-
tation within the stroma and stroma interaction, and commu-
nication with the immune system to avoid attack. Once in the
blood stream, cells have to survive trapping by the coagulation
system, to survive shear stress in small blood vessels, and to
find the right location for extravasation. Once outside in the
metastatic locus, tumor cells have to learn the communication
with the “foreign” stroma cells to establish vascular supply
and again express molecules, which induce immune tolerance.
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Lung carcinomas when detected are most often in a metastatic
stage IV. Lung carcinomas metastasize by lymphatic as well as
blood vessels.When careful evaluation is done in resected lung
carcinomas, vascular invasion is often seen in low-stage
tumors, which usually results in increased incidence of recur-
rence as well as shortened survival of the patient [1]. Whereas
metastasis via the lymphatic route usually takes longer until
distant metastases are set, spreading via blood vessels will set
early on distant metastases. Lung carcinomas have some pref-
erential sites for metastasis, such as the brain, bones, and adre-
nal glands. Other organs are involved usually in late stage of
the disease. Within the different types of lung carcinomas,
there is also a preferential metastatic site, such as liver metas-
tasis in small-cell lung carcinoma (SCLC) and brain metastasis
in SCLC and adenocarcinoma [2–4]. In recent years, brain
metastasis are increasingly seen in adenocarcinomas with epi-
dermal growth factor receptor (EGFR) mutations and
EML4ALK1 rearrangement, whereas squamous cell carcino-
mas in many cases have a tendency to locally invade the tho-
racic wall [4, 5]. This opens a variety of questions on metasta-
sis in lung carcinomas, which we aim to address in this review.
When dissecting metastasis into developmental steps, there
are several ways to approach this theme, including the first step
of invasion into the stroma. Due to space limits, we will not
discuss the process of precursor to in situ carcinoma transition
and also will not focus on stroma invasion. We will focus on
(a) Tumor establishment and cell migration, followed by
(b) Vascular invasion—lymphatic and hematologic,
(c) Extravasation, and finally, end with
(d) Creating the distant metastatic focus.
1 Tumor establishment and cell migration
After tumor cells have invaded the stroma, several tasks have
to be organized. To promote tumor growth, the tumor cells
need to organize vascular supply for nutrition and oxygen
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uptake. For movement within the stroma, this needs to be
restructured; the tumor cells have to escape lymphocytic at-
tacks; and finally, for migration, the tumor cells have to adapt
to a migratory cell structure.
1.1 Angiogenesis, hypoxia, and stroma
(microenvironment)
When tumor cells start to form nodules within the stroma, they
need to communicate with the surrounding microenviron-
ment, which is composed mainly by macrophages, fibro-
blasts/myofibroblasts, neutrophils, lymphocytes, and dendrit-
ic cells. To facilitate angiogenesis, tumor cells can either di-
rectly release angiogenic factors such as vascular endothelial
growth factors (VEGFs) to directly stimulate the formation of
new blood vessels, or tumor cells cooperate with macro-
phages, which can release angiogenic growth factors [6–8].
A good example for angiogenesis induced by tumor cells is
the vascular variant of squamous cell dysplasia, whereas in
well-differentiated adenocarcinomas, angiogenesis seems to
relay on cooperating macrophages [9–12] (Figs. 1a, b and
2a). To understand the function of macrophages, it is neces-
sary to briefly discuss the two different populations of macro-
phages, the M1 and M2 types. M1 macrophages are acting
against tumor cell invasion by secreting interleukin 12 (IL-
12), which function tumoricidal by an interaction with cyto-
toxic lymphocytes and NK cells. M2 macrophages produce
IL-10, which promote tumor progression. The differentiation
of naïve macrophages into either M1 orM2 types is facilitated
by NOTCH, where low Notch via SOCS3 drives macro-
phages into M2 types [13]. M1 macrophages act proinflam-
matory, inactivate autophagy by production of radical oxygen
species, and can also induce apoptosis of tumor cells [14–16].
Notably, mutation and inactivation of Notch are found in neu-
roendocrine carcinomas, whereas activation in other non-
small-cell carcinomas, which questions the function of this
gene as either oncogene or tumor suppressor [17–20]. Most
probably different members of the Notch family proteins func-
tion differently in squamous cell, small cell, and adenocarci-
nomas and in addition, act differently during tumor develop-
ment [21–23].
1.1.1 The role of hypoxia in tumor cell migration
and metastasis
As the primary tumor grows, usually the formation of new
blood vessels cannot keep with this resulting in hypoxia.
This is the time when tumor cells are faced with this problem
and try to escape apoptosis induced by hypoxia. Some of these
mechanisms have been elucidated. HIF1α is upregulated in
areas of tumor hypoxia [24–28], and if translocated into the
nucleus and bind to HIF1β can induce transcription of VEGF,
thus increasing the formation of more blood vessels.
Apoptosis is also inhibited by growth factors such as IGF
and EGF, which are also induced by hypoxia [24, 29].
Carcinoma cells also escape apoptosis and cell death in hyp-
oxic areas by reducing their metabolism and cell division [30].
In mouse models of lung adenocarcinomas driven by the mu-
tated RAS oncogene, invasion was exclusively seen starting in
areas of necrosis and hypoxia [31] (Fig. 3a, b). This fits wells
with published data from human tumor research, showing that
migration and epithelial to mesenchymal transition (EMT) are
increased in hypoxic areas by the release of different proteins
[32–36]. If each of these enzymes/proteins act in concert to-
gether or if each of these factors can act independently is
presently unknown.
Macrophages also act together with fibroblasts and
myofibroblasts to form either a stroma suitable for tumor cell
invasion and migration or might inhibit migration (Fig. 2b).
Fig. 1 Angiogenesis in preneoplastic lesions, a atypical adenomatous
hyperplasia has no new vessels but instead relies on the normal vascular
architecture of preexisting alveolar septa; in the vascular variant of
squamous cell dysplasia, b the preneoplastic cells induce angiogenesis
using vascular growth factors produced by the dysplastic cells
Fig. 2 Desmoplastic stroma reaction is almost absent in this well-
differentiated lepidic predominant adenocarcinoma (a) whereas
prominent in this squamous cell carcinoma (b)
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This can easily be evaluated by morphology. In case the stro-
ma cells form a classical scar, this means inhibition for the
tumor cells to migrate, whereas desmoplastic stroma is a form
of stroma remodeling done by myofibroblasts, which enable
tumor cells to migrate (Fig. 4a, b). Usually, fibroblasts in scars
do not cooperate with tumor cells; myofibroblasts in contrary
cooperate [37, 38]. In some cases, even tumor cells undergo-
ing EMT directly form part of the desmoplastic stroma as in
pleomorphic carcinomas (Fig. 5a, b) and occasionally also in
SCLC [39]. Several studies have shown that tumor-associated
Bfibroblasts^ (essentially myofibroblasts in the lung) are dif-
ferent from normal fibroblasts in the lung. They express dif-
ferent genes and proteins related to their function in cancer
development. Specifically, MLH1 was upregulated, whereas
COX1, FGFR4, Smad3, and p120 were downregulated [40].
Factors have been identified, which drive this differentiation
of mesenchymal stem cells into myofibroblasts, namely, TGF-
beta and IL-1β. TGF-β also induces the expression ofα-SMA
and FAP-α [41]. Serine protease fibroblast activation protein
(FAP) promotes tumor growth in an endogenous mouse
model of lung cancer driven by the K-rasG12D mutant. On
the contrary, FAP depletion inhibits tumor cell proliferation
indirectly by increasing collagen accumulation, decreasing
myofibroblasts in number, and decreasing blood vessel
density in tumors [42]. Most importantly, myofibroblasts also
express metalloproteinases (MMPs) such asMMP-2,MMP-9,
MMP-8, and MMP-7. So these cells actively take part in
remodeling of matrix proteins. In addition, MMP-8 actively
participates in the process of fibrocyte migration [43].
In this context, also changes of matrix proteins, their com-
position, and their orientation are important for tumor cell
migration. Usually, the matrix is composed of several proteins
such as different types of collagen (I, III, IV, and V; predom-
inant collagen I), fibronectin, laminin, elastin, and osteonectin.
These proteins provide stability to the stroma by their oriented
deposition and network formation by cross-linking. They also
serve as orientation molecules providing ligands for migrating
leukocytes expressing adhesionmolecules. This mechanism is
also used by migrating tumor cells. As a further benefit, adhe-
sion of SCLC cells to fibronectin, laminin, and collagen IV
through β1 integrins confers resistance to apoptosis induced
by standard chemotherapeutic agents. Adhesion to ECM pro-
teins stimulated protein tyrosine kinase (PTK) activity in both
untreated and etoposide-treated cells [44]. In non-small-cell
Fig. 3 Experimental adenocarcinoma in a mouse. Carcinoma is induced
by mutant KRAS. At a certain size of the in situ adenocarcinoma, central
hypoxic necrosis develops (a), which is the prerequisite for invasion (b)
Fig. 4 Desmoplastic stroma supports invasion and guides the carcinoma
cells in this squamous cell carcinoma (a), whereas scar tissue inhibits
invasion as in this adenocarcinoma example (b). The only way for the
carcinoma cells is invasion into lymphatics, which happened in the center
Fig. 5 Epithelial to mesenchymal transition (EMT) is common in
pleomorphic carcinomas of the lung (a); this can also be demonstrated
by cytokeratin immunohistochemistry, showing epithelial tumor cells
positively stained on the left side, whereas tumor cells at the right side
have lost cytokeratin and acquired vimentin (b)
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lung carcinoma (NSCLC), osteonectin (SPARC; normally on-
ly in bronchial cartilages) is selectively synthesized by the
cells of the tumor stroma in case of intratumoral hypoxia
and acidity. Osteonectin proven by immunohistochemistry fa-
vors cancer cell invasion and migration [45].
Another important factor is the orientation and composition
of matrix proteins. High amounts of elastin favor resistance
for tumor cell migration, whereas high collagen and organized
oriented deposition promote tumor cell migration.
Conversely, direct cell contacts between tumor cells and fibro-
blasts can also create migratory-inhibitory matrix composed
of unorganized collagens (I, III, IV, and V) and proteoglycans
(biglycan, fibromodulin, perlecan, and versican). The thick
desmoplastic fibers bundles can inhibit the migration and in-
vasion of tumor cells [46]. Matrix protein deposition seems to
be in addition regulated by a tumor suppressor gene, frequent-
ly lost in lung cancer, RBM5 (RNA-binding motif protein 5;
chromosome 3p21.3). The encoded protein plays a role in the
induction of cell cycle arrest and apoptosis. Loss of RBM5
causes upregulation of Rac1, β-catenin, collagen, and lami-
nin, which in turn increase cell movement. Consequently,
Rac1 and β-catenin correlate positively with lymph node me-
tastasis in lung cancer patients [47]. Two other matrix proteins
are less explored. Expression of periostin is associated with
vimentin expression in the stroma or tumor epithelia and cor-
relates with higher stage. The correlation of periostin expres-
sion with that of versican and collagen in advanced tumors
was less obvious. Opposite to periostin, expression of elastin
was associated with less advanced disease [39]. However, this
observation still needs confirmation as well as more in-depth
investigation for the function of these proteins.
So, invasion, tumor growth, and tumor cell migration of
lung cancer cells are regulated by many different factors, as
cytokines, adhesionmolecules and receptors, and genes acting
either directly on tumor cells or cells of the microenvironment.
1.2 Escaping immune cell attack
Usually, tumor cells produce many modified proteins,
which are recognized as foreign by dendritic cells and
lymphocytes. Tumor cells are therefore attacked and
destroyed by cytotoxic lymphocytes (CD8+). However,
pulmonary carcinoma cells have developed different es-
cape mechanisms to prevent this cytotoxic attack. By
modulating the innate immune system, macrophages
are preferentially forced to differentiate into M2 types
as already explained. Another mechanism to protect tu-
mor cell is to modify the pool of antigen presenting
dendritic cells (DCs). Within dendritic cells, several
functional quite opposite acting cell populations are
discerned; conventional DC will present tumor antigens
to T lymphocytes and force the production of cytotoxic
T cells, whereas plasmocytoid and monocytoid DCs act
as tumor protective cells. For example, Bombesin de-
rived from SCLC inhibits IL-12 production by DC and
their ability to activate T cells [48]. Tumor cells by
secretion of TGF-β and prostaglandin E2 induce DCs
t o d i f f e r e n t i a t e i n t o r e g u l a t o r y DCs w i t h a
CD11c(low)CD11b(high) phenotype (also named
plasmocytoid DC) and high expressions of IL-10, VEGF,
and arginase I. These regulatory plasmocytoid DCs inhibited
CD4+ T cell proliferation [49] and thus act protumorigenic.
Another action to prevent cytotoxic lymphocyte attack is to
induce an influx of regulatory T cells (Treg). Treg downregu-
late the production and influx of cytotoxic Tcells and NK cells
and promote immune tolerance [50–52]. Finally, also bone
marrow-derived myeloid precursor cells (MDSCs) may
downregulate a T cell-based immune reaction towards grow-
ing tumor cells by secreting arginase I [53]. Indoleamine 2,3-
dioxygenase (IDO) and IL-6 seem to play a regulatory role for
these MDSCs, as downregulation of IDO resulted in reduced
lung tumor burden and improved survival in experimental
settings. Loss of IDO resulted in an impairment of
protumorigenic MDSC, whereas IL-6 recovered both MDSC
suppressor function and metastasis susceptibility. In addition,
vascular density was significantly reduced in Ido1-
nullizygous mice [54].
In some carcinomas, preferentially in pulmonary squa-
mous cell carcinomas, eosinophils are found in abundance.
The role eosinophilic granulocytes play in NSCLC is not
fully understood. It may be that variants of IL-17 (IL-17E)
induce a helper 2 type of immune response, which in turn
by the release of IL-4 and IL-5 causes tissue eosinophilia.
In one study, it was shown that IL-17E has antitumor
activity. Injections of recombinant IL-17E resulted in sig-
nificant antitumor activity. Combining IL-17E with chemo-
therapy increased the antitumor efficacy in a xenograft
model [55]. If eosinophils are directly acting cytotoxic
against the tumor cells, for example, by releasing cytotoxic
basic proteins was not explored in this study.
1.3 Migration
After having established the primary tumor and organized
nutrition as well as protection for immune cell attacks, the
tumor cells have to acquire changes to migrate to distant sites
and establish metastasis. There are two different forms how
tumor cells migrate, single-cell or small-cell cluster movement
as it is seen in small-cell carcinoma as well as undifferentiated
NSCLC and movement by large clusters of organized cells
such as in acinar adenocarcinoma or some cases of squamous
cell carcinoma (Figs. 6a, b, 7a, b, and 8a, b). For single cell
and small clusters, migration seems to be much easier since
single cells can more easily adapt, for example, a spindle cell
morphology, which enables better movement. Tumor cells
during migration reduce or even abolish cytokeratin filaments
78 Cancer Metastasis Rev (2016) 35:75–91
and increase/or de novo express α-actin and vimentin; this is
commonly seen in pleomorphic carcinomas (Fig. 5b), carci-
nosarcomas, high-grade squamous cell and adenocarcinomas,
and SCLC. Lung adenocarcinomas with high smooth muscle
actin gene ACTA2 expression showed significantly enhanced
distant metastasis and unfavorable prognosis. ACTA2 down-
regulation remarkably impaired in vitro migration, invasion,
clonogenicity, and transendothelial penetration of adenocarci-
noma cells without affecting proliferation. ACTA2 upregula-
tion in lung adenocarcinoma cells was also connected to ex-
pression of c-MET and focal adhesion kinase (FAK), whereas
ACTA2 targeting by small interfering RNAs (siRNAs) and
short hairpin RNAs (shRNAs) resulted in loss of
mesenchymal characteristics [56]. Migration within the stro-
ma requires several changes in tumor cells, one is formation of
invadopodia. Tyrosine kinase substrate 5 (Tks5) is a scaffold-
ing protein necessary for the formation of invadopodia. There
are different isoforms, some of them (short isoforms) associ-
ated with reduced other (long isoforms) increased metastasis
[57–59]. Expression of Tks5 together with the expression of
α-actin is further regulated by cortactin and neural Wiskott-
Aldrich syndrome protein (N-WASP), which also regulate the
expression of metalloprotease membrane type 1 matrix
metalloprotease (MMP14) [58]. However, migration of tumor
cells seems to be regulated by different genes, so probably,
there is not a single mechanism for each tumor type, but more
likely that tumor cells individually have adapted different
mechanisms of migration protocols and used it during carci-
nogenesis. As an example, myosin heavy chain 9 (MYH9)
and Copine III (CPNE3) positively correlate with the migra-
tion and invasion properties of lung cancer cell lines. If
CPNE3 was knocked down, the metastatic abilities were
inhibited in a mouse model. Also, CPNE3 protein expression
levels were positively correlated with the clinical stage in
NSCLC [60]. In another study, nestin protein expression sig-
nificantly correlated with tumor size and lymph node metas-
tasis in NSCLC and also poor survival in patients with
Fig. 6 Tumor cell migration, a this small-cell neuroendocrine carcinoma
moves in small-cell groups, whereas the adenocarcinoma (b) moves
almost as single cell
Fig. 7 Tumor cell migration, a
this mixed small- and large-cell
neuroendocrine carcinoma
migrates as single- or small-cell
clusters, whereas the small-cell
neuroendocrine carcinoma in b
migrates in small complexes in
this very early stage; experimental
mouse model (slides provided by
A. Gazdar)
Fig. 8 Tumor cell migration, a a mucinous adenocarcinoma moves in
larger-cell complexes along the alveolar walls, still using the supply by
the alveolar septa and b an unusual 3D complex of squamous cells
moving as spheroids
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adenocarcinoma. Nestin inhibition by shRNA decreased pro-
liferation, migration, invasion, and sphere formation in adeno-
carcinoma cells [61]. One of the major studied mechanisms of
tumor cell migration is EMT, which again is seen in tumors
with single-cell or small-cluster migration type (Fig. 9a–c).
When looking up studies on EMT, a huge amount of pub-
lished article can be found in databases. The major surprise is
that different genes are associated with EMT. And even when
focusing on lung cancer studies, there are still different genes
found to trigger EMT. Some of the most often found EMT-
associated genes are Twist, Snail, and TGFβ1.
Suppression of Twist expression in metastatic mammary
carcinoma cells inhibits their ability to metastasize from the
mammary gland to the lung. Ectopic expression of Twist re-
sulted in loss of E-cadherin-mediated adhesion, activation of
mesenchymal markers, and induction of cell motility, suggest-
ing that Twist promotes EMT [62]. In another study, Twist
was selectively associated with EGFR-mutated adenocarci-
nomas. Twist expressed in lung adenocarcinoma cell lines
with EGFR mutation showed increased cell mobility. A de-
crease of EGFR pathway through EGF retrieval or inhibition
of Twist expression by small RNA reversed the phenomenon.
These findings supported that Twist promotes EMT in EGFR-
mutated lung adenocarcinoma [63]. In the study by Pirozzi,
the focus was on TGFβ1. They used two epithelial cell lines
which acquired a fibroblast-like appearance when treated by
TGFβ1. By inhibiting TGFβ1, vimentin and CD90 were
downregulated and cytokeratin, E-cadherin, and CD326 were
upregulated. TGFβ1 also upregulated Slug, Twist, and β-ca-
tenin, thus confirming EMT. Interestingly, also some stem cell
markers as Oct4, Nanog, Sox2, and CD133 were
overexpressed too, linking EMT to tumor stem cells [64].
Adhesion plays a major role in EMT; therefore, not surpris-
ingly, studies have focused onWnt, catenin, and GSK3β path-
way. Loss of SARI (suppressor of AP-1, also called BATF2)
expression initiates EMT, causing repression of E-cadherin
and upregulation of vimentin in lung adenocarcinoma cell
lines and in human lung adenocarcinomas. By knockdown
endogenous SARI in a human lung xenograft-mouse model,
multiple lymph node metastases developed. SARI has been
shown to regulate EMT by modulating the (GSK)-3beta-beta-
catenin signaling pathway [65]. In the study by Blaukovitsch,
another pathway for EMT was shown; Snail and Twist were
not involved in pulmonary sarcomatoid carcinomas but
instead upregulation of c-Jun and consecutive overexpressions
of Vimentin and Fascin were seen [66].
When dissecting sites of metastasis, the way EMT is regu-
lated get more diverse; PREP1 accumulation was found in a
large number of human brain metastases of various solid tu-
mors, including NSCLC. PREP1 induces the expression of
multiple activator protein 1 components including Fos-
related antigen 1 (FRA-1). FRA-1 and PBX1 are required
for EMT triggered by PREP1 in lung tumor cells [67]. The
study by Shen showed that increased levels of long non-
coding RNAmetastasis-associated lung adenocarcinoma tran-
script 1 (MALAT1) promotes lung cancer brain metastasis by
EMT, whereas silencing of MALAT1 inhibits lung cancer cell
migration and metastasis in the brain [68]. So far, nothing
similar was investigated for bone metastasis by pulmonary
carcinomas.
So far, we have focused on single-cell and small-
cluster migration. However, in surgical pathology rou-
tine, most well-differentiated carcinomas including lung
Fig. 9 a EMT in a pleomorphic carcinoma with spindle cells and b, c
EMT in mouse model of KRAS-induced adenocarcinomas with
additional expression of mutant TP53. c Movat stain, which better
demonstrates the invasion of the spindle tumor cells into the
desmoplastic stroma
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carcinomas move in large cell clusters; for example,
acinar adenocarcinomas will show nice structured acini
deep within the stroma and even within blood
vessels (Fig. 10a, b). The mechanisms how these tumor
cells manage their coordinated movement by retaining
their epithelial structure is almost unknown. These car-
cinomas do not undergo EMT. Recently, in an investi-
gation using drosophila border cells as a model, the
processes of migration of large-cell complexes were elu-
cidated. By RNAi silencing, 360 conserved signaling
transduction genes were knocked down to identify es-
sential pathways for border cell migration. The follow-
ing four genes associated with TGF-beta signaling were
identified: Rack1 (receptor of activated C kinase), brk
(brinker), mad (mother against dpp), and sax (saxo-
phone). Inhibition of Src activity by Rack1 may be
important for border cell migration and cluster cohesion
maintenance. Although this study focused on signaling
pathways involved in collective migration during em-
bryogenesis and organogenesis, these data could be the
first step in understanding migration of carcinoma com-
plex cancer metastasis [69].
2 Vascular invasion, lymphatic/hematologic
2.1 Blood vessels
Tumor cells orient themselves along adhesion molecules as
expressed by matrix proteins, but in addition, they also sense
for oxygen and most probably also orient themselves for
higher oxygen tension [70]. Invasion into blood vessels is very
similar to invasion into the stroma. Tumor cells have already
learned to degrade proteins of the basal lamina at the epithelial
border, and similar proteins form the matrix of small blood
vessels. Forming holes into the basal lamina of these blood
vessels is therefore easily done, and tumor cells migrate into
the intima. However, a new problem arises for tumor cells
within the circulation, shear stress due to tumor cell deforma-
tion in small blood vessels and the problem with coagulation.
Shear stress is usually well tolerated by those tumor cells
which underwent EMT. Tumor cells expressing Vimentin and
α-actin can adapt to the capillary diameters, but cells still
expressing cytokeratins might burst. This is one of the reasons
why a majority of tumor cells do not survive within the circu-
lation [71]. With respect to coagulation, tumor cells on one
hand have to avoid being trapped within a blood clot but on
the other hand, will need a clot to slow down the speed of the
blood stream, attach to the clot, and use it for extravasation
[72]. Clot formation might be induced by tissue factor being
produced and released by macrophages. Impairment of mac-
rophage function decreased tumor cell survival without alter-
ing clot formation, demonstrating that the recruitment of func-
tional macrophages was essential for tumor cell survival [73].
Another way how tumor cells might trigger clot formation has
been demonstrated in mucinous adenocarcinomas. Mucins se-
creted by the tumor cells induced platelet aggregation and
furthermore interacted with L-selectin and platelet-derived
P-selectin without thrombin generation [74]. This interaction
already points to the next step, adherence to vascular walls for
extravasation. Coming back to tumor cell trapping by blood
clots, it seems that carcinoma cells require the assistance of
macrophages and granulocytes for fibrinolysis. In a study of
lung carcinomas, fibrinolytic components as tissue plasmino-
gen activators (t-PA) and the inhibitors PAI-1 and PAI-2 were
all negative in tumor cells, whereas urokinase-specific anti-
bodies stained loosely packed tumor cells and macrophages.
Both PAI-1 and PAI-2 were most prominently expressed with-
in interstitial and alveolar macrophages [75]. In another study
analyzing pulmonary adenocarcinomas, a positive correlation
was found between Ets-1 and urokinase-type plasminogen
activator (u-PA) expression [76].
2.2 Lymphatic vessels
Invasion into lymph vessels is easier than into blood vessels
due to the tiny wall of the former. In addition, carcinoma cells
Fig. 10 Vascular invasion, a tumor cells are scattered in acinar
complexes within the intima of this pulmonary artery and b large acinar
and papillary adenocarcinoma complexes can be seen within these blood
vessels, demonstrating the other example of invasion as large tumor cell
complexes
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might already enter the lymphatic stream by the interstitial
channels of the lymph draining system. On the contrary,
lymph vessels can easily be congested by tumor cells. This
can reverse the lymph flow, which might explain unusual sites
of lymph node metastasis and so-called skip lesions. In con-
trast to the situation within blood vessels, carcinoma cells in
lymphatics have to deal with the immune system. So, survival
is dependent on induction of immune cell escape mechanisms
(see above).
Whereas carcinoma cells entering the blood stream might
early onset distant metastasis and thus shorten overall survival
of the patient [1], propagation of carcinoma cells along the
lymphatics will set distant metastasis later. These tumor cells
will set primarily metastasis within regional lymph nodes.
3 Extravasation
Carcinoma cells have to escape the circulation. However, the
process how tumor cells select their final destination is still not
clear. A lot of information was gained from studies on homing
mechanisms of lymphocytes and extravasation of
granulocytes. The most important site are venules with high
endothelia. First of all, the blood flow is reduced, which en-
ables tumor cells to roll over the endothelia and express adhe-
sion molecules. These adhesion molecules need to find their
respective and specific receptors for adhesion. Once adhering
to the endothelia, tumor cells have to activate the coagulation
system for better and firm adherence, followed by production
of holes between endothelia for migration out of the vessel
lumen. Several factors have been identified, such as caveolin,
which increases cell permeability. Loss of caveolin results in
increased phosphorylation of VEGFR-2 and decreased asso-
ciation with the adherence junction protein, VE-cadherin.
Loss of caveolin increases endothelial permeability and tumor
growth [77]. Tumor cells might use different selectins such as
E-selectin and P-selectin to adhere to specific sites on the
endothelia of venules. Also, other selectins might be used, as
has been shown by knockout of these selectins. PSGL-1,
CD44, and CEA could be detected in SCLC cells. By intravi-
tal microscopy, SCLC cells were shown to roll along vessel
walls mimicking leukocyte behavior [78].
4 Creating the distant metastatic focus
It is well known that few tumor cells survive within the circu-
lation. Even more, from those tumor cells, which survive and
finally leave the circulation and settle at a distant site, only a
small proportion progress and form metastatic nodules [71].
Usually, single-tumor cells die (probably with the exception of
small-cell carcinoma cells), and small clusters form
micronodules but do not grow further. Another enigma is the
selection of metastatic sites. In general, lung cancer cells pre-
fer the brain, bones, adrenal glands, and within lung carcino-
ma types, small-cell neuroendocrine carcinomas as well as
adenocarcinomas metastasize into the brain, whereas squa-
mous cell carcinomas prefer bones. What homing mecha-
nisms are in action? And moreover, how carcinoma cells com-
municate with this new stroma? For example, in the brain,
carcinoma cells need to organize their new homing by com-
municating with glial cells and also manipulate microglia to
prevent attacks by immune cells and finally induce angiogen-
esis for their supply in nutrients and oxygen. In the following
paragraphs, we will focus on different aspects of homing,
extravasation, and creation of a metastatic niche in different
organs.
To leave the circulation, lung cancer cells need signals,
which seem to be specific for each organ. Some of these, such
as E-selectin, are used in several carcinomas including breast
and lung. Systemic inflammation may increase the expression
of E-selectin, which mediate lung metastasis of an experimen-
tal breast cancer model [79]. Hyperpermeability is also a fac-
tor important for homing, because this slows down the blood
flow and enable rolling of the tumor cells over the endothelia.
Hyperpermeability is mediated by endothelial cell FAK,
which upregulates E-selectin, leading to preferential homing
of metastatic cancer cells to these foci [80]. Attachment of
tumor cells however needs an activation of several other ad-
hesion molecules. Once tumor cell attach on endothelia, they
cause the induction of vascular cell adhesion molecule-1
(VCAM-1) and vascular adhesion protein-1 (VAP-1), which
is dependent on tumor cell-clot formation, induced by tissue
coagulation factors [81]. Also, changes in the cell to cell junc-
tions of endothelia are necessary for the tumor cells, to move
through interendothelial gaps. This is facilitated by an over-
expression of angiopoietin-2 [82]. In addition, also MD-2, a
coreceptor for toll-like receptor 4, triggers the formation of
regions of hyperpermeability in mice by upregulating C-C
chemokine receptor type 2 (CCR2) expression. The CCR2-
CCL2 system induces the abundant secretion of permeability
factors such as serum amyloid A3 and S100A8 [83].
Since all these investigations use different models and an-
alyze different tumor tissues/or none, it is not surprising that
other investigators found different acting molecules. Using
cell cultures from an aggressive human squamous cell carci-
noma, Chen subcultured different tumor clones and showed a
different expression profile for members of the β1 integrin
family. By the intravenous inoculation into SCID mice, the
clonotypes differed in VLA-1 and VLA-2 expressions, where
high levels of VLA-1 and VLA-2 display an increase in me-
tastasis [84]. The group by Sadanandam identified 11 unique
peptides specific for homing to lung, liver, bone marrow, or
brain. Semaphorin 5A and its receptor plexin B3 were identi-
fied as relevant for homing to these organ sites [85]. A major
factor for homing of carcinoma cells, including colon, lung,
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and breast, is the chemokine receptor CXCR4. The unique
function of CXCR4 is to promote the homing of tumor cells
to their microenvironment at the distant organ sites [86].
Acute inflammations seem to promote CXCR4 expression
and may alter the lung microenvironment and prepare it for
a metastatic Bniche^ [87]. CXCR4 inhibition reduced the in-
flux of myeloid-derived cells and impaired lung metastases.
CXCR4 is specifically expressed in stromal cells that prepare
the protumor microenvironment [88].
Several other signaling proteins are also involved in metasta-
tic homing and formation of a metastatic focus; however, how
these different molecules interact with each other is not known.
In a study looking for the relationship of microRNA
(miRNA) and metastasis, Liu et al. found that expression of
miR-26a dramatically enhanced lung cancer cell migration
and invasion. Matrix metallopeptidase 2 (MMP-2), VEGF,
Twist, and β-catenin were upregulated. Phosphatase and
tensin homolog (PTEN) was a direct target of miR-26a.
They found that miR-26a increased AKT phosphorylation
and nuclear factor kappa B (NFκB) activation. So, miR-26a
enhanced lung cancer metastasis via activation of AKT path-
way by PTEN suppression [89]. MALAT1-deficient cells are
impaired in migration and form fewer tumor nodules in a
mouse xenograft. Gene expression of MALAT1 is critical
for lung cancer metastasis [90]. In addition, in another inves-
tigation, it was shown that MALAT1 cooperates with eIF4A1
and thymosin β4 in promoting metastasis in NSCLC [91].
4.1 Angiogenesis
Angiogenesis at the metastatic site in one part follows the same
principles as in the primary focus; however, there is one major
problem. Whereas at the primary focus lung carcinoma cells
cross-talk with stroma cells by mechanisms and transmitters
which have been developed during the process of developing
from the precursor lesion to in situ carcinoma to invasive car-
cinoma, this cross-talk is different in the new metastatic site.
Brain glial cells or bone marrow stroma cells might response to
other signals than those stroma cells within the lung. So, the
major developmental step to establish a metastatic focus is
communication with the stroma, and further, more communi-
cation might be different depending on the location. In one
investigation, a bridge was built between angiogenesis at the
primary and metastatic sites. CXCL12 was expressed in tumor
cells and in tumor vessels; CXCR7was expressed by tumor and
endothelial cells in the primary tumor and in the brain metasta-
sis. CXCR4 showed a nuclear positivity in all samples, but only
CXCL12 expression in tumor endothelial cells was significant-
ly correlated with shorter survival [92].
In interaction with stroma, there are no published data
which could highlight general mechanisms by which lung
carcinoma cells communicate with their stromal counterparts;
however, communication at different organ sites have been
studied and therefore will be discussed in the following
paragraph.
4.2 Metastasis
When discussing metastasis, many questions arise, which are
still incompletely answered. When does metastasis occur? Is
there a need for a certain size of the primary tumor that cells
leave and start migrating? Are tumor cells randomly moving
out from the tumor or are these selective clones, and are these
genetically different from the dominant clone? Do carcinoma
cells move collectively or as single cells? These questions
have been discussed extensively in the literature, but especial-
ly when comparing metastasis in lung cancer, several good
examples are there to answer at least some of these questions.
Small-cell neuroendocrine carcinoma has some unique fea-
tures. When looking at the invasion front, it is evident that this
carcinoma prefers migration of single-cell and small-cell clus-
ters composed of three to five cells (Figs. 6a, and 7a). In blood
and lymphatic vessels, SCLC usually presents with single
cells or small clusters of cells. Quite common is the finding
of several large brain metastases and a very small primary
tumor, which might even escape the detection by HRCT.
This raises the question of early migration of carcinoma cells
from the initial focus and setting metastasis early in the tumor
development. In contrast, squamous cell carcinoma can form a
large primary tumor, and when surgically removed has not
formed metastasis; even some cases have not set regional
lymph node metastasis. Migrating squamous cell carcinoma
(SCC) often form large complexes of cells and when seen
intravascular again present with large cell complexes. So, both
extremes do occur in lung carcinomas. In adenocarcinomas,
both types of migration and metastasis do occur, usually large
migrating complexes of well-differentiated acinar or papillary
adenocarcinomas (Fig. 11a), and small-cell clusters of solid or
mucinous adenocarcinomas. The aspect of genetic
Fig. 11 Brain metastasis, a cells of an adenocarcinoma interacting with
astrocytes and microglial cells and b large adenocarcinoma complexes
have acquired huge areas of the brain but in addition, imitate ependymal
structures
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heterogeneity in primary and metastatic tumor clones has been
investigated in studies comparing primary and metastatic car-
cinomas. More importantly, it seems that not only primary
carcinomas are different from metastasis but also metastases
are different among each other. To be clear, driver mutations
or general genetic aberrations in primary and secondary tu-
mors are still identical, but additional genetic modifications
arose within the metastases.
When looking up the frequency of metastasis of lung car-
cinomas, there are some preferential sites, as bone 34.3 %,
lung 32.1 %, brain 28.4 %, adrenals 16.7 %, and liver
13.4 % [3]. We will discuss some of these, depending on the
availability of research data.
4.2.1 Brain metastasis
Research coming from brain metastasis of breast and NSCLC
have raised several important findings. First metastatic carci-
nomas can colonize the brain in different ways. Renal cell
carcinomas most often form metastases which are well
circumscribed and grow not out of the microglia pseudocap-
sule, whereas SCLCs tend to form small metastatic foci and
tumor cells grown into the microglia pseudocapsule and be-
yond into brain parenchyma. This has nicely been demonstrat-
ed by a coculture system consisting of an organotypic mouse
brain slice and epithelial cells embedded in matrigel (3D cell
sphere) [93]. In addition by the same group of researchers, it
has been shown that microglia support invasion and coloniza-
tion of brain tissue by breast and lung cancer cells. This is
under the control of the Wnt pathway, as upregulation of
Dickkopf-2, an inhibitor of Wnt, inactivates the prometastatic
function of microglia. Similar to tumor dentritic cell interac-
tion, bacterial lipopolysacharide shifts tumor-educated mi-
croglia into a classical M1 phenotype, reduces their
proinvasive function, and unmasks inflammatory and Wnt
signaling as the most strongly regulated pathways [94].
Several factors have been identified as being specifically in-
volved in regulating brain metastasis, but so far, these are still
isolated factors, and the main question how these different
factors interact remains unanswered.
Among the different cells of the brain, astrocytes seem to
serve invading carcinoma cells. Astrocytes secrete matrix
metalloprotease-2 (MMP-2) and MMP-9 that proactively in-
duced human lung and breast tumor cell invasion and metas-
tasis formation [95]. In addition, factors from the coagulation
cascade are important. Plasmin acts as a defense against met-
astatic invasion by converting membrane-bound astrocytic
FasL into a paracrine death signal for cancer cells and by
inactivating the axon path-finding molecule L1CAM, which
metastatic cells express for spreading along brain capillaries
and for metastatic outgrowth. But, metastatic carcinoma cells
from lung and breast secrete neuroserpin and serpin B2 to
prevent plasmin generation and its metastasis-suppressive
effects [96]. Within the Wnt pathway, LEF1/TCF4 acts inde-
pendently of β-catenin in cerebrally metastasized human lung
adenocarcinomas [97]. Downregulation of E-cadherin was al-
so observed in a majority of adenocarcinoma and small-cell
lung cancer samples. LOH of the CDH1 gene was frequently
found in SCLC. Altered expression of Dishevelled-1,
Dishevelled-3, E-cadherin, and beta-catenin were present in
brain metastases of SCLC and adenocarcinoma, again
pointing to the importance of the Wnt signaling [98]. In an-
other study, peritumoral brain edema was shown to be associ-
ated with increased β-catenin, E-cadherin, and decreased
CD44v6 and caspase-9 expressions in brain metastatic squa-
mous cell carcinoma [99]. These findings were confirmed in
another study showing a significant correlation of increased
collagen XVII in adenocarcinoma and increased caspase-9,
CD44v6, and decreased cellular apoptosis susceptibility pro-
tein (CAS) and Ki-67 in squamous cell carcinoma in brain
metastasis [100].
Interestingly, when looking up adenocarcinomas with
ALK1 rearrangement, FGFR1 gene amplification correlated
significantly with brain metastases. Although in these cases
there were also higher numbers of visceral metastases, FGFR1
amplifications in brain metastases of adenocarcinomas were
fivefoldmore frequent than in the primary tumors [68]. Also, a
cross-talk of EGFR-MET was reported in adenocarcinomas
with brain metastasis. This was not a direct interaction but a
signaling via the activation of mitogen-activated protein ki-
nases (MAPKs). EGFR-MET cross-talk was independent
from the mutation status of EGFR. MET signaling promoted
migration and invasion. MET inhibition decreased the
incidence of brain metastasis [101]. Also, CXCR4
seems to play a role in brain metastasis. CXCR4 protein
was highly overexpressed in patients with brain-specific
metastasis but significantly less in NSCLC patients with
other organ metastases and without metastases [102].
Another factor ADAM9 levels were relatively higher
in brain metastases than the levels observed in primary
lung tumors. ADAM9 regulates lung cancer metastasis
to the brain by facilitating the tPA-mediated cleavage of
CDCP1 [103]. In a subsequent study, it was shown that
ADAM9 regulated miR-218, which targets CDH2 in
aggressive lung cancer cells. The downregulation of
ADAM9 upregulated SLIT2 and miR-218, which to-
gether downregulated CDH2 expression. This study re-
vealed that ADAM9 activates CDH2 through the release
of miR-218 inhibition on CDH2 in lung adenocarcino-
ma [104].
A lot of interesting studies focused on the comparison of
genomic alterations between primary lung carcinomas versus
brain and bone metastases. The hypothesis is that there might
be a clonal diversity between these two. It is still not clear if
genetic differences between the primary tumor and the meta-
static site is a primary event; i.e., clones are existing within the
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primary tumor, or if these are secondary events, reflecting the
interaction of the carcinoma cells with the microenvironment
and the cells therein. Wrage et al. found gene copy number
variations between primary and CNS metastasis by array
CGH. Genes with amplified copy numbers in primary and
metastatic tumors were related to DNA replication and mis-
match repair. Genes only amplified in the metastatic tumor
were related to leukocyte migration and organ development.
Genes with a lower copy number in the metastatic tumor were
related to proteolysis, negative regulation of cell proliferation,
and cell adhesion [105].
As with many marker studies focusing on single gene/pro-
tein, a selection bias or just an overinterpretation does occur.
We already discussed MALAT1 in the setting of invasion and
metastasis. Shen and coworkers found higher levels of
MALAT1 in brain metastases compared to other
extrapulmonary sites. In the in vitro experiments, it turned out
that the major function of this lnRNA is EMT [68]. What can
be concluded is that EMT seems to be required for tumor cells
invading brain tissues, but MALAT1 is not a brain metastasis
gene per se. A similar investigation searched for brain metas-
tasis genes and came up with an EMT regulator; pre-B cell
leukemia homeobox (Pbx)-regulating protein-1 (Prep1) over-
expression triggered EMT, whereas PREP1 downregulation
inhibits the induction of EMT in response to TGF-β. PREP1
modulates the sensitivity to SMAD3 and induces the expres-
sion of Fos-related antigen 1 (FRA-1). Both FRA-1 and PBX1
are required for the mesenchymal changes triggered by PREP1
in lung tumor cells. PREP1-induced mesenchymal transforma-
tion correlates with increased lung colonization, and PREP1
accumulation was found in human brain metastases [67].
Similarly, migration seems to play a role in brain metastasis,
not surprisingly, since migration is often associated with EMT.
Han et al. showed that knockdown of KDM5B and SIRT1
genes specifically inhibits lung cancer cell migration in vitro.
SIRT1 was highly expressed in brain metastasis. Using other
lung cancer cell lines, the authors showed that the function of
SIRT1 correlates with cell migration [106]. There are not many
studies looking for the influence of molecules of the adhesin
family. Nasser and colleagues investigated E-cadherin expres-
sion. Low E-cadherin expression was associated with increased
risk of developing brain metastasis. By treating tumor in a
mouse model with pioglitazone, a peroxisome proliferator-ac-
tivated receptor γ-activating drug prevented loss of E-cadherin
expression and reduced expressions of MMP9 and fibronectin
and furthermore, the development of brain metastasis [107].
Two studies showed an association of genotypic variants
with brain metastasis. In the study by Li et al. [108], genotypes
for AKT1 and PI3Kwere associated with brain metastasis risk
(AKT1 rs2498804, AKT1 rs2494732, and PIK3CA
rs2699887). In another study by Li [109], genotype variations
for SMAD6 (rs12913975) and INHBC (rs4760259) were as-
sociated with risk of brain metastasis.
Whereas most studies on brain metastasis focused on the
most common lung adenocarcinoma, Paik and coworkers
studied squamous cell carcinomas, which rarely present with
brain metastasis. They found “truncal” PTEN loss and PI3K-
aberrant tumors to be associated with brain metastases. There
was also a genetic heterogeneity between lung primaries and
brain metastases [110].
4.2.2 Lung metastasis
Although pulmonary metastasis is common in adenocarci-
nomas as well as SCLC, not much is known about specific
molecular mechanisms. In the study by Ruoslathi, connexin-
43 was identified as adhesion molecule facilitating Bhoming^
to the lung endothelial cells. Connexin-43 was highly upreg-
ulated in tumor cells during endothelial cell contact [111].
4.2.3 Bone metastasis
In bone metastasis, research reports focused on two different
aspects of colonization, homing mechanisms and interaction
of carcinoma cells with the bone/bone marrow stroma. In the
work of Yang, PDGFRβ was found to be the main tyrosine
kinase expressed in BM stromal ST-2 and MC3T3-E1
preosteoblastic cells. Incubation of ST-2 and human BM en-
dothelial cells with sunitinib, a PDGFRβ inhibitor, led to
growth inhibition and induction of apoptosis. Sunitinib pro-
duced extensive disruption of tissue architecture and vessel
leakage in the BM cavity. Pretreatment of ST-2 cells with
sunitinib hindered adhesion to lung cancer cell lines.
Pretreatment of mice with sunitinib before intracardiac inocu-
lation of A549M1 or H460M5 cells caused marked inhibition
of tumor cells homing to bone, whereas no effect was found
when tumor cells were pretreated before inoculation [112].
Several studies focused on the reaction of osteoclasts, which
cell type seems to be important for creating a metastatic
Bniche^ for tumor cells in the bone.
Knockdown of DDR1 by siRNA showed reduced inva-
siveness in collagen matrices and increased apoptosis.
Conditioned media of DDR1 knockdown cells decreased
osteoclastogenic activity in vitro. In a bone metastasis model
lacking DDR1, decreased metastatic activity and reduced tu-
mor burden and osteolytic lesions were achieved. These re-
sulted also in a substantial reduction of tumor cells reaching
the bone compartment [113]. Vincent et al. showed induction
of TGF-β-dependent osteoclastogenic bone resorption and
enhanced stroma-dependent metalloproteolytic activities by
TCF4 and PRKD3 and anchorage-related proteins MCAM
and SUSD5 resulting in aggressive osseous colonization
[114]. In another study, stromal cell-derived factor-1 (SDF-
1) secreted by osteoblasts and bone marrow stromal cells en-
hanced the invasiveness of lung cancer cells by increasing
MMP-9 expression through the CXCR4/ERK/NFκB signal
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transduction pathway [115]. In another approach, researchers
focused on miRNAs associated with bone metastasis of lung
cancer. Seven miRNAs were downregulated and 21 miRNAs
were upregulated in lung adenocarcinoma. Functional bioin-
formatic annotation analysis indicated that the MAPK, Wnt,
and NFκB signaling pathways, as well as pathways involving
the matrix metalloproteinase, cytoskeletal protein, and angio-
genesis factors, are involved in orchestrating bone metastasis
[116]. Finally, in the study by Luis-Ravelo, the function of
RHOB, a small GTPase, was investigated. Gene silencing of
RHOB prevented metastatic activity in a systemic murine
model of bone metastasis. Consistently, high RHOB levels
promote metastasis progression [117].
A new promising aspect came with the demonstration that
the RANK-RANK ligand system regulates the activity of os-
teoclasts. CCL22 upregulated receptor activator of nuclear
factor-κB ligand (RANKL) in osteoclast-like cells which sub-
sequently induced cell migration and also enhanced phosphor-
ylation of protein kinase B/Akt and extracellular signal-regu-
lated kinase (ERK). This suggests that osteoclasts may pro-
mote bone metastasis of cancer cells expressing CCR4 in the
bone marrow by producing its ligand CCL22 [118]. Lung
cancer metastases to bone produce primarily mixed
osteolytic/osteoblastic lesions (Fig. 12a, b). Treatment with
RANK antibody limited the formation of lytic lesions and
inhibited the rate of in vivo tumor growth [119]. The study
by Kuo and coworkers studied the regulation and interaction
of parathyroid hormone-related protein (PTHrP). The authors
showed that miR-33a levels are inversely correlated with
PTHrP expression. The reintroduction of miR-33a reduces
the production of osteoclastogenesis activator RANKL and
macrophage colony-stimulating factor (M-CSF) on
osteoblasts, while the expression of PTHrP was decreased.
In addition, miR-33a-mediated PTHrP downregulation results
in decreased IL-8 secretion and contributes to decreased lung
cancer-mediated osteoclast differentiation and bone resorption
in experimental setting [120]. Peng and colleagues showed
upregulated RANKL, RANK, and OPG in NSCLC cell lines
and in tumor tissues with bone metastasis. Migration and in-
vasion were significantly enhanced by recombinant human
RANKL and transfection of RANKL cDNA and were im-
paired after OPG was added. Differential expressions of
RANKL, RANK, and OPG were shown to be associated with
the metastatic potential of human NSCLC to skeleton [121].
This was confirmed by the study of Miller. Tumor cell-medi-
ated osteolysis occurs through induction of RANKL. The au-
thors tested this hypothesis in novel NSCLC bone metastasis
mouse models. They found that OPG-Fc reduced the devel-
opment and progression of osteolytic lesions. OPG-Fc plus
docetaxel in combination resulted in significantly greater in-
hibition of skeletal tumor growth compared to either single
agent alone. The inhibition of RANKL reduced osteolytic
bone destruction and skeletal tumor burden [122].
Dougall and coworkers used denosumab, a fully human
monoclonal antibody against RANKL, and demonstrated pre-
vention or delay of skeletal-related events in patients with
solid tumors that have metastasized to bone. Besides the role
of RANKL in tumor-induced osteolysis, bone destruction, and
skeletal tumor progression, the authors also provided argu-
ments for a direct pro-metastatic effect of RANKL, as
RANKL also stimulates metastasis via activity on RANK-ex-
pressing cancer cells, resulting in increased invasion and mi-
gration [123].
4.2.4 Pleural metastasis
Lung carcinomas frequently metastasize to the pleura.
Especially, adenocarcinomas because of their peripheral loca-
tion invade early on the pleura. Interestingly, when comparing
adenocarcinomas with known driver mutation, it is evident
that adenocarcinomas with EML4-ALK1 rearrangement have
a higher propensity for pleura metastasis and malignant effu-
sion [124]. In one study, it was proposed that the 216G/T
polymorphism of the EGF receptor may play a role in pleural
metastasis by overexpressing the protein [125].
4.3 Lymph nodes
Although lymph nodes are among the first metastatic foci of
lung carcinomas, much less is known about specific molecular
events in facilitating this colonization. Peng et al. studied the
effect of hypoxia and chemokines. CCR7 expression correlat-
ed positively with HIF-1α and HIF-2α, and all together cor-
related with lymph nodemetastasis. It was shown that hypoxia
induced HIF-1α and HIF-2α expression, which upregulated
Fig. 12 Bone metastasis, a adenocarcinoma cell complexes have
induced an impressive activity of osteoclasts, resulting in lytic bone
lesions; b adenocarcinoma metastases have induced bleeding and a
massive inflammatory reaction, which also results in lytic bone lesions
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CCR7; inhibiting HIF-1α or HIF-2α resulted in decreased
CCR7 expression and furthermore in inhibition of tumor cell
migration and invasion [126]. However, it seems obvious that
more than these three molecules are involved, which has been
shown by a study on genetic aberrations. Gains at 7q36, 8p12,
10q22, and 12p12; loss at 4p14; and the homozygous dele-
tions at 4q occurred significantly more frequent in SCC from
patients with lymph nodemetastases only. Gains at 7q, 8p, and
10q were restricted to SCC with lymph node metastasis, and
gain at 8q was restricted to patients with distant metastasis
[127].
In summarizing our knowledge in the metastatic process in
lung carcinomas, it can be stated that many mechanisms and
involved genes/proteins have been identified, but the major
breakthrough is still not achieved. The major problem is that
the process of metastasis has so many steps that we still do not
overlook the interactions of hypoxia, migration, EMT and
MET, homing, interaction with stoma cells, and preparation
of the metastatic niche, which probably occur not as a time
sequence but more likely in parallel.
Finally, we will not discuss metastasis to the lung, although
there are complementing factors hidden, which might help in
understanding homingmechanisms, such as the exclusive me-
tastasis of glioblastomas and meningosarcomas to the lung.
But, this would too much expand this review.
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